title: Regulation of the MET oncogene: molecular mechanisms.
abstract: The MET oncogene is a predictive biomarker and an attractive therapeutic target for various cancers. Its expression is regulated at multiple layers via various mechanisms. It is subject to epigenetic modifications, i.e. DNA methylation and histone acetylation. Hypomethylation and acetylation of the MET gene have been associated with its high expression in some cancers. Multiple transcription factors including Sp1 and Ets-1 govern its transcription. After its transcription, METmRNA is spliced into multiple species in the nucleus before being transported to the cytoplasm where its translation is modulated by at least 30 microRNAs and translation initiation factors, e.g. eIF4E and eIF4B. METmRNA produces a single chain pro-Met protein of 170 kDa which is cleaved into α and β chains. These two chains are bound together through disulfide bonds to form a heterodimer which undergoes either N-linked or O-linked glycosylation in the Golgi apparatus before it is properly localized in the membrane. Upon interactions with its ligand, i.e. hepatocyte growth factor (HGF), the activity of Met kinase is boosted through various phosphorylation mechanisms and the Met signal is relayed to downstream pathways. The phosphorylated Met is then internalized for subsequent degradation or recycle via proteasome, lysosome or endosome pathways. Moreover, the Met expression is subject to autoregulation and activation by other EGFRs and G-protein coupled receptors. Since deregulation of the MET gene leads to cancer and other pathological conditions, a better understanding of the MET regulation is critical for Met-targeted therapeutics.
authors.affiliation: Research and Development, Ventana Medical Systems, Inc., a Member of the Roche Group, Oro Valley, AZ 85755, USA jian.zhang.jz9@roche.com.
authors.forename: Jack
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Research and Development, Ventana Medical Systems, Inc., a Member of the Roche Group, Oro Valley, AZ 85755, USA jian.zhang.jz9@roche.com andy.babic@roche.com.
authors.forename: Andy
authors.initials: A
authors.lastname: Babic
mesh_terms: D017398:Alternative Splicing; D015972:Gene Expression Regulation, Neoplastic; D006031:Glycosylation; D006801:Humans; D009857:Oncogenes; D014176:Protein Biosynthesis; D059748:Proteolysis; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D014157:Transcription Factors / Q000502:physiology
chemical_list: D014157:Transcription Factors; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met